COMPUMEDICS LIMITED — AGM Information 2008

Nov 24, 2008

==> picture [721 x 271] intentionally omitted <==

Slide 1

Agenda

• Meeting opens

• Chairman's address

• Ordinary business

• Meeting closes

Slide 2

Chairman’s address

Slide 3

Over view

		�	Financial update – highlights
		�	Financial update - details
		�	Business unit revenues
		�	Geographic revenues
		�	Key activities completed
		�	Early FY2009 performance
		�	Outlook – financial
		�	Outlook – technology
		�	Recap
Slide	4

• Record revenues at $38.5m despite the then strong Australian dollar

• FY2008 profits and operating cash significantly grow yearon-year, 515% and 125% respectively

• � Operating costs stable despite investing activities

• � Debt reduced year-on-year by a further 18%

• � R&D pipeline maintained

• SomniLink® SPAP® close to first shipment

• “Compumedics’ financials continue to improve!”

Slide 5

Financial update - details

• Gross margins stable at approximately 58% despite strengthening Australian dollar

• Operating expenses less investing activities stable with last years spending - $19.1m compared to $19.5m in the prior year

• EBITDA up to $1.9m profit compared to prior year profit of $1.3m, a 46% increase over the prior year

• Profit after tax up to $0.8m compared to the prior year profit of $0.1m, a 515% increase over the prior year

Slide 6

Financial update - details

.

• Borrowings were reduced by a further 18% from $3.4 in the prior year to $2.8m at end of FY2008

• Borrowing costs at $0.7m were 18% lower than the prior year’s $0.9m

• Sales in USA (+10%), Australia (+12%) and DWL (+4%) were up but sales in Europe declined (-14%), the latter primarily being attributable to business specific issues

• � Net Foreign exchange was a $0.7m loss for FY2008 being $0.3m better than the $1.0m loss in FY2007

Slide 7

Financial update - details

	2005 actual	2006 actual	2007 actual	2008 actual
Revenues ($m)	38.2	37.7	36.7	38.5
Margins %	53%	52%	58%	58%
Other income	0.3	1.3	0.1	0.4
Operating Expenses	24.3	22.1	19.5	20.3
EBITDA	(2.6)	(0.5)	1.3	1.9
NPAT	(4.7)	(1.6)	0.1	0.8
AUD/USD exchange rate	0.76	0.73	0.84	0.96

Slide 8

Financial update - details

Total group sales stabilised despite rising Australian dollar

==> picture [503 x 299] intentionally omitted <==

----- Start of picture text -----

Revenue growth
curtailed in
45 AUD’s
DWL acquisition
40
35
30
25 Neuroscan
AUDm acquisition
20
15
10
5
0
2002 2003 2004 2005 2006 2007 2008
Total sales FX adjusted sales
----- End of picture text -----

==> picture [27 x 7] intentionally omitted <==

----- Start of picture text -----

Slide 9
----- End of picture text -----

Financial update - details

Gross Margins % improving as a result of on-going restructuring and cost improvements programs and despite the surging Australian dollar

==> picture [476 x 260] intentionally omitted <==

----- Start of picture text -----

60
50
40
% 30
20
10
0
2002 2003 2004 2005 2006 2007 2008
----- End of picture text -----

Slide 10

Financial update - details

Operating Expenses stable despite cost pressures and investing activities for future revenue growth

==> picture [515 x 262] intentionally omitted <==

----- Start of picture text -----

$1.2m charge
25 for investing
activities
DWL acquisition
20
Neuroscan
15 acquisition
AUDm
10
5
0
2002 2003 2004 2005 2006 2007 2008
----- End of picture text -----

==> picture [32 x 7] intentionally omitted <==

----- Start of picture text -----

Slide 11
----- End of picture text -----

Financial update - details

EBITDA continues to grow

==> picture [507 x 254] intentionally omitted <==

----- Start of picture text -----

3
2
1
AUDm 0
-1
-2
-3
2002 2003 2004 2005 2006 2007 2008
----- End of picture text -----

Slide 12

Financial update - details

==> picture [508 x 302] intentionally omitted <==

----- Start of picture text -----

Debt continues to decline – a further 18% reduction
year-on-year
9
Neuroscan
8 acquisition
7
DWL acquisition
6
5
AUDm
4
3
2
1
0
2002 2003 2004 2005 2006 2007 2008
----- End of picture text -----

Slide 13

Financial update - details

Financing costs begin to decline – 18% year-on-year

==> picture [515 x 249] intentionally omitted <==

----- Start of picture text -----

0.9
0.8
0.7
0.6
0.5
AUDm
0.4
0.3
0.2
0.1
0
2002 2003 2004 2005 2006 2007 2008
----- End of picture text -----

Slide 14

Financial update - details

Foreign exchange impacts adversely in current financial year

==> picture [510 x 259] intentionally omitted <==

----- Start of picture text -----

Exchange movements relate
0.6 largely to consolidation of off
shore group subsidiaries
0.4
0.2
0
AUDm -0.2
-0.4
-0.6
-0.8
-1
2002 2003 2004 2005 2006 2007 2008
----- End of picture text -----

Slide 15

Business unit revenues

Business unit revenues stable across all business units with annuity-style supplies revenues increasing

==> picture [499 x 272] intentionally omitted <==

----- Start of picture text -----

20
18
16
14
12
AUDm 10
8
6
4
2
0
2002 2003 2004 2005 2006 2007 2008
Sleep Brain research EEG/DWL Supplies/Service
----- End of picture text -----

Slide 16

Geographic revenues

==> picture [721 x 395] intentionally omitted <==

----- Start of picture text -----

MI
Australia 2008 F Y
Asia 1%
2006 FY 12% Austr al i a
20% Asia
16%
17%
Europe
26%
Eur ope
USA
MI 26%
USA
42%
1%
40%
Asia Australia
13% 14%
Europe
USA 29%
43%
2007 FY
Slide 17
----- End of picture text -----

Key achievements completed in FY2008

• Revenues increase 5% despite a 14% increase in the Australian dollar to the US dollar at that time

• � First full year of sub-lease of the Melbourne office reflected in the results

• SomniLink® SPAP® product close to commercial shipping

• � Neuvo® long term monitoring EEG device first sales booked

• New Xegis® EMG device added to the product basket via an OEM agreement completed January 2008

Slide 18

Early FY2009 performance update

• Compumedics, like all entities in the current environment, is having to deal with rapidly changing and unpredictable circumstances.

• The Company remains firmly focused on achieving profitable growth despite the adverse and unique external circumstances we find ourselves in.

• The substantial fall (some 30%) in the Australian dollar to the US dollar will assist the Company in its goal to continue to grow profitably.

• The Company has yet to finalise its bank review and is working closely with its bankers to implement the most appropriate funding arrangements for the Company into the future.

Slide 19

Outlook – financial

� The Company is currently implementing the most significant new product release program in the Company’s history. The following three new product releases are into the existing core medical diagnostic business:

• Grael PSG – the next generation laboratory based sleep diagnostic system is being released into existing markets

• Neuvo® Long Term Monitoring EEG device – recently commenced selling into Europe. This device takes Compumedics into a new and substantial EEG market for the Company

• Xegis® EMG device – recently commenced selling into Europe and Asia. This device also takes Compumedics into a new and complementary market to the EEG market

� In addition, the Company is soon to commence commercial shipping of its first medical treatment device into the substantial sleep-treatment market – the SomniLink® SPAP®

� A substantial reorganisation of the Company’s sales and marketing resources for the sleep diagnostic and EEG/Brain Research markets in Europe, the Middle East and Africa has been implemented.

Slide 20

Outlook - technology

Building a global medical diagnostic company

==> picture [155 x 103] intentionally omitted <==

----- Start of picture text -----

DWL
Blood Flow
Neuroscan Diagnostics
Sleep
Diagnostics
Neuro
Neuro
Diagnostics Medical
Supplies
----- End of picture text -----

• With Compumedics’ core strategic edge being Sleep Diagnostics

• Leveraging this technology into related fields including Neurosciences, Cardiology, Brain Research, Neuromedical supplies. Combined, these markets have annual sales of more than AUD1.2 billion.

• In 2002, Compumedics acquired US-based Neuroscan, the world’s leading developer of brain research instruments.

• In 2004, Compumedics acquired German based DWL, which has enabled Compumedics to expand its global operations into neuro- and cardio-diagnostics and equipment for brain research.

• From 1999-2007, the Company increased its sales from $9 million to almost $40 million, reflecting its product development initiatives, combined with its own strong distribution network in the United States, which accounts for 43% of sales. 86% of sales are exported world-wide.

Slide 21

Outlook - technology

New Products Xegis® Neuvo®

Slide 22

Outlook - technology

No other company has the world’s leading technology and/or market position covering 3 of the key rapid-growth new-generation medical technology market first discovered in the 1980s

• Clinical Sleep

• Transcranial Doppler (TCD)

• Computerised Cognitive Neuroscience/EEG brain function

Slide 23

Outlook - technology

Sleep Market

==> picture [146 x 121] intentionally omitted <==

• Pioneering of computerised PSG (CMP;1987) and CPAP treatment discovery [Sullivan, CE (1981), Sydney Australia]

==> picture [166 x 61] intentionally omitted <==

• 40% of the Australian Clinical EEG Market and 70% of the Australian Sleep Diagnostics Market.

Sleep Heart Health Study

• 10% USA market share and growing in sleep diagnostics.

• � Developed and installed Australia’s first computerised sleep centre at Melbourne’s Epworth Hospital in 1988.

Slide 24

Outlook - technology

• Transcranial Doppler (TCD) Market

• � Developed by Dr. Rune Aaslid in 1982, today DWL’s client

• DWL has a strong market share in Germany and well established distribution networks in Europe

• World’s firsts include :

==> picture [120 x 159] intentionally omitted <==

• Bilateral Doppler ,

• ● Emboli differentiation ● Full digital Doppler

Slide 25

Outlook - technology

Computerised Cognitive Neuroscience/EEG brain function

• Pioneered by Neuroscan in 1989

• Commands 90% of the US Market for research EEG applications and a significant market share world-wide.

• Sells its products in over 50 countries world-wide to over 1500 universities, corporate laboratories and national research centres.

• First to commercialise high-density EEG/EP recordings, electromagnetic source localisation, merging of multimodal neuroimaging data.

==> picture [89 x 52] intentionally omitted <==

==> picture [155 x 154] intentionally omitted <==

• World opportunity - $1.2b size of the industry, of which .

• the Company has less than 3% market share

Slide 26

Business Recap

• Record revenues despite the strong Australian dollar in F2008.

• EBITDA, profits after tax and operating cash flows all improving year-on-year.

• Debt further reduced by 18% year-on-year to $2.8m and below in recent months.

• Cost vigilance to remain.

• R&D product pipeline strong.

• Focus remains on restoring group growth and increasing profitability.

Slide 27

Ordinary business

• Item 1 Financial Statements and Reports (non-binding resolution)

• Item 2 Election of a Director

• Item 3 Adoption of Remuneration Report (non-binding resolution)

• Item 4 Removal of auditor

• Item 5 Appointment of auditor

Slide 28

==> picture [721 x 271] intentionally omitted <==

Slide 29